Pfizer Inc. PFE
Pfizer destroyed $20-60bn of value since 2019 despite a $40bn COVID windfall; Starboard wants the board to hold Bourla accountable for peer-median R&D/M&A returns.
Thesis
Pfizer has dramatically underperformed peers and the S&P 500 since 2019, losing an estimated $20-60bn of shareholder value even after a roughly $40bn COVID cash windfall. Starboard argues the root cause is collapsing R&D and M&A productivity: CEO Albert Bourla publicly committed in 2018-2019 to delivering '15 potential blockbusters' by 2022 but most of those programs missed, while subsequent deals including the $43bn Seagen acquisition and the $5.4bn Global Blood Therapeutics purchase (whose lead drug Oxbryta was pulled in September 2024) were struck at 3.3-5.1x peak sales versus a 2.4x market median. Consensus implies just a 15% revenue return on $128bn of cumulative R&D plus M&A spend, worst in the peer group against a 38% median. Starboard is pressing the board to enforce accountability and drive 2030 revenue to $79bn and EPS above $4.25.
SCQA
Pfizer is one of the world's largest pharmaceutical companies, operating across primary care, specialty care, and oncology, generating roughly $58bn of 2023 revenue and playing a critical public-health role through its COVID-19 vaccine and Paxlovid antiviral.
Since 2019 Pfizer's stock has returned minus 13% while peers rallied 120%; despite a $40bn COVID windfall, management missed its '15 blockbusters in 5 years' pledge, overpaid on ~$70bn of M&A, and posted worst-in-class R&D returns.
The board must actively hold management accountable for capital-allocation discipline on R&D and M&A, measuring success by revenue return on invested capital and demanding at minimum the 38% peer-median productivity rather than the current 15%.
Achieving peer-median returns implies ~$79bn of 2030 revenue and adjusted EPS above $4.25, supporting a re-rating from today's 10x P/E toward the 14x peer median and roughly doubling the share price.
The three reasons
- 1
Pfizer lost $20-60bn of market value since 2019 despite a ~$40bn COVID cash windfall
- 2
CEO Bourla's 2018 pledge of '15 blockbusters in 5 years' has largely failed to materialize
- 3
15% revenue return on $128bn R&D and M&A spend - worst-in-class vs 38% peer median
Primary demands
- Board must actively hold management accountable for R&D and M&A capital-allocation returns
- Drive expected revenue return on R&D plus M&A from 15% to at least the 38% peer median
- Achieve ~$79bn of 2030 revenue and >$4.25 adjusted EPS (ex-COVID)
- Restore management credibility after missed 2024 guidance and failed deals (e.g. Oxbryta/GBT)
- Apply greater discipline on future M&A multiples and deal selection
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Eli Lilly and Novo Nordisk GLP-1 franchises (Mounjaro/Zepbound, Ozempic/Wegovy) as peer innovation benchmark
- Prevnar 20 as example of Pfizer's own prior innovation success
Notable slides (6)
Notes
Classic Starboard deck structure: praise management for COVID achievements up front, then systematically dismantle the record using management's own quotes (Bourla's 'best pipeline ever' and '15 blockbusters in 5 years' at pp. 13-18) and peer-gap charts. Argument built around four pillars: (A) lack of internal innovation 2019-2023, (B) lack of expected future innovation (including missed GLP-1 opportunity), (C) overpaid capital allocation (~$70bn M&A at 3.3-5.1x peak sales), (D) forecasting/budgeting failures (FY23 COVID miss, FY24 EPS miss). Closing 'conclusion' section re-litigates the same points and frames ask as board-level accountability rather than specific board seats or breakup - softer than a proxy fight deck. PDF is sourced from 10xEBITDA.com (watermark visible on all slides); presented at the October 2024 13D Monitor Active-Passive Investor Summit. No explicit stake percentage disclosed in the deck itself. Deck builds heavy use of CEO quote contradiction as its core rhetorical device - unusually quote-dense for a Starboard presentation.